6-Bromo-1-phenylquinolin-2-one | 914918-88-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 6-Bromo-1-phenylquinolin-2-one
• CAS: 914918-88-0
• 化学式: C₁₅H₁₀BrNO
• 分子量: 300.154
• InChiKey: CVSLRGSGSRWNHX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  18
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  20.3
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  6-溴喹啉-2-酮 、 苯硼酸 在 copper diacetate 吡啶 作用下， 以 二氯甲烷 为溶剂， 反应 48.0h， 生成 6-Bromo-1-phenylquinolin-2-one
  参考文献：
  名称：

  WO2006/122154

  摘要：

  公开号：

文献信息

• METHOD OF MODULATING STRESS-ACTIVATED PROTEIN KINASE SYSTEM
  申请人：Blatt Lawrence M.

  公开号：US20120258924A1

  公开（公告）日：2012-10-11

  Disclosed are methods of modulating a stress activated protein kinase (SAPK) system with an active compound, wherein the active compound exhibits low potency for inhibition of at least one p38 MAPK; and wherein the contacting is conducted at a SAPK-modulating concentration that is at a low percentage inhibitory concentration for inhibition of the at least one p38 MAPK by the compound. Also disclosed are derivatives of pirfenidone. These derivatives can modulate a stress activated protein kinase (SAPK) system.

  本发明涉及使用活性化合物调节应激激活蛋白激酶（SAPK）系统的方法，其中该活性化合物对至少一种p38 MAPK抑制的效力较低；并且该接触是在该化合物对至少一种p38 MAPK的抑制浓度低百分比的SAPK调节浓度下进行的。本发明还涉及吡非尼酮的衍生物，这些衍生物可以调节应激激活蛋白激酶（SAPK）系统。
• Method of modulating stress-activated protein kinase system
  申请人：Intermune, Inc.

  公开号：EP2426134A2

  公开（公告）日：2012-03-07

  It has now been discovered that a high therapeutic effect in treating various disorders associated with enhanced activity of kinase p38 may be achieved by using a potent p38? kinase inhibitor compound which also has inhibitory activity against p38?. Furthermore, reducing the activities of both kinase p38? and kinase p38? without reducing the activity of a kinase p38? to such an extent that undesired side effects are observed upon administration to a subject having a disorder associated with enhanced activity of kinase p38 has been discovered to be achievable by modifying inhibitors of p38? such that the modification engenders inhibitory activity against p38?. Described are compounds with activity against p38? and p38?.; Disclosed are methods of using described compounds and compositions to modulate a stress activated protein kinase (SAPK) system with an active compound, wherein the active compound exhibits inhibition of the p38? and p38? MAPKs. Also disclosed are methods for identifying compounds which inhibit p38? and p38? MAPKs and which can modulate a stress activated protein kinase (SAPK) system.

  现已发现，通过使用一种对 p38?激酶也具有抑制活性的强效 p38?激酶抑制剂化合物，可以在治疗与 p38?激酶活性增强有关的各种疾病方面取得很高的治疗效果。此外，已经发现通过修饰 p38?的抑制剂，使其对 p38?具有抑制活性，可以降低激酶 p38?和激酶 p38?的活性，而不会降低激酶 p38?的活性，以至于在对患有与激酶 p38?活性增强相关的疾病的受试者用药时观察到不期望的副作用。和p38?的活性的化合物；公开了使用所述化合物和组合物以活性化合物调节应激活化蛋白激酶(SAPK)系统的方法，其中活性化合物表现出抑制p38?MAPKs 的抑制作用。还公开了鉴定抑制 p38?和 p38?MAPKs 并能调节应激活化蛋白激酶（SAPK）系统的化合物的方法。
• Pyridine-2-one-derivatives as modulators of stress-activated protein kinase system
  申请人：Intermune, Inc.

  公开号：EP2591784A1

  公开（公告）日：2013-05-15

  Disclosed are methods of modulating a stress activated protein kinase (SAPK) system with an active compound, wherein the active compound exhibits low potency for inhibition of at least one p38 MAPK; and wherein the contacting is conducted at a SAPK-modulating concentration that is at a low percentage inhibitory concentration for inhibition of the at least one p38 MAPK by the compound. Also disclosed are derivatives of pirfenidone. These derivatives can modulate a stress activated protein kinase (SAPK) system.

  公开了用活性化合物调节应激活化蛋白激酶（SAPK）系统的方法，其中活性化合物对抑制至少一种p38 MAPK表现出较低的效力；并且接触是在SAPK调节浓度下进行的，该浓度是化合物抑制至少一种p38 MAPK的低百分比抑制浓度。还公开了吡非尼酮的衍生物。这些衍生物可以调节应激活化蛋白激酶（SAPK）系统。
• PYRIDONE DERIVATIVES FOR MODULATING STRESS-ACTIVATED PROTEIN KINASE SYSTEM
  申请人：Intermune, Inc.

  公开号：EP1928454B1

  公开（公告）日：2014-09-24
• METHODS FOR TREATING ACUTE MYOCARDIAL INFARCTIONS AND ASSOCIATED DISORDERS
  申请人：Olgin Jeff

  公开号：US20100190731A1

  公开（公告）日：2010-07-29

  The invention relates to methods of treating patients who have suffered an acute myocardial infarction (AMI) with a therapeutic that has anti-fibrotic effects, for example, pirfenidone and analogs thereof.